Aligos Therapeutics Inc
$ 8.74
1.16%
14 Apr - close price
- Market Cap 53,463,000 USD
- Current Price $ 8.74
- High / Low $ 8.97 / 8.42
- Stock P/E N/A
- Book Value 8.67
- EPS -2.67
- Next Earning Report 2026-05-05
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.69 %
- ROE -1.97 %
- 52 Week High 13.69
- 52 Week Low 4.20
About
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, is focused on developing novel therapies to address unmet medical needs in viral and liver diseases. The company is headquartered in South San Francisco, California.
Analyst Target Price
$65.80
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-03-05 | 2025-11-06 | 2025-08-06 | 2025-05-05 | 2025-03-10 | 2024-11-06 | 2024-08-06 | 2024-05-07 | 2024-03-12 | 2023-11-02 | 2023-08-03 | 2023-05-04 |
| Reported EPS | -1.91 | -3.04 | -1.53 | -2.1133 | -13.1 | -3.07 | 0.03 | -0.22 | -0.22 | -0.41 | -0.43 | -0.53 |
| Estimated EPS | -2.4873 | -0.25 | -0.24 | -3.1533 | -3.67 | -2.16 | -0.16 | -0.19 | -0.27 | -0.47 | -0.49 | -0.48 |
| Surprise | 0.5773 | -2.79 | -1.29 | 1.04 | -9.43 | -0.91 | 0.19 | -0.03 | 0.05 | 0.06 | 0.06 | -0.05 |
| Surprise Percentage | 23.2099% | -1116% | -537.5% | 32.9813% | -256.9482% | -42.1296% | 118.75% | -15.7895% | 18.5185% | 12.766% | 12.2449% | -10.4167% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-05 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | -2.29 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: ALGS
2026-04-14 20:38:47
Aligos Therapeutics (ALGS) announced that its Data Safety Monitoring Board (DSMB) has recommended an increase in the sample size for the HBeAg- cohort in its ongoing study, following a positive interim analysis. Additionally, the FDA granted Fast Track Designation to pevifoscorvir sodium, Aligos's drug candidate, for the treatment of chronic HBV, which will facilitate enhanced regulatory interaction. Enrollment completion for the HBeAg- cohort is anticipated by the second half of 2026, with topline data expected in 2027.
2026-04-14 20:38:47
This article lists 12 healthcare stocks that experienced significant movement during Tuesday's after-market session, with some gaining and others losing value. Notable gainers include BNB Plus, Hoth Therapeutics, and Actuate Therapeutics, while HeartBeam, Aligos Therapeutics, and Immunic Inc. were among the decliners. The piece provides percentage changes in stock prices and market capitalization for each mentioned company.
2026-04-14 20:38:47
Aligos Therapeutics (ALGS) announced preliminary results from its Phase 2 B-SUPREME trial for chronic hepatitis B. The independent Data Safety Monitoring Board recommended expanding the study's sample size to improve statistical power after futility criteria were not met, though the drug's safety profile remains favorable. Aligos anticipates completing enrollment for a cohort by late 2026, with topline results expected in 2027.
2026-04-14 20:38:47
Aligos Therapeutics announced the first interim analysis results from its Phase 2 B-SUPREME study of pevifoscorvir sodium for chronic hepatitis B virus (HBV) infection, with the independent Data Safety Monitoring Review Board recommending an increase in sample size for the HBeAg- cohort. The company also received FDA Fast Track Designation for pevifoscorvir sodium, a potential best-in-class capsid assembly modulator. The study drugs were well-tolerated, and topline data is expected in 2027.
2026-04-14 20:38:47
Aligos Therapeutics announced that its hepatitis B drug candidate, pevifoscorvir sodium, has been granted FDA Fast Track Designation, which could accelerate its development and review process. The company also reported interim Phase 2 data for its B-SUPREME study, with an independent safety board recommending continuation and an increased sample size for the HBeAg- cohort. Topline data from the study is still expected in 2027.
2026-04-14 19:38:47
Aligos Therapeutics announced that its hepatitis B drug candidate, pevifoscorvir sodium, has been granted FDA Fast Track Designation. This comes after the first interim analysis of its Phase 2 B-SUPREME study, where the DSMB recommended increasing the sample size for one cohort to optimize statistical power, without meeting futility criteria. Despite positive developments, the company's stock, ALGS, saw a negative market reaction, dropping over 10%.
